A groundbreaking annual injection designed to protect against Human Immunodeficiency Virus (HIV) has successfully ...

Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...

Researchers led by Imperial have unveiled primary trial results that show encouraging advances in HIV treatment driven by ...

Lenacapavir, which stops HIV from replicating inside cells, has passed early safety tests.

UCSF researchers are the first to confirm that this approach is effective for the patients who need it most. Patients who struggle to take daily HIV pills may benefit from long-acting injectable ...

Two more people have been potentially cured of HIV after receiving stem cell transplants to treat blood cancer or bone marrow ...

Offering mailed self-testing for HIV encouraged patients to test themselves for HIV but require methods of improving ...

Immunocore’s big swing for a functional HIV cure has cleared its first hurdle. | Immunocore’s big swing for a functional HIV ...

To reduce care disparities and prevent them from exacerbating among people living with HIV who have long COVID, education and ...

Already, significant harm has been done to inhibit progress combating HIV/AIDS, and the next four years could return us to ...

SAN FRANCISCO -- Most patients with HIV who received two broadly neutralizing antibodies (bNAbs) after pausing antiretroviral ...

Debates over tuberculosis reporting began in the late 19th century, when the bacterial infection was reframed not as a disease of the elite but of the urban poor. New York City was the first in the ...